nodes	percent_of_prediction	percent_of_DWPC	metapath
Crizotinib—TYK2—cardiovascular system—attention deficit hyperactivity disorder	0.00214	0.00368	CbGeAlD
Crizotinib—TESK1—midbrain—attention deficit hyperactivity disorder	0.00213	0.00366	CbGeAlD
Crizotinib—EPHB6—forebrain—attention deficit hyperactivity disorder	0.00212	0.00365	CbGeAlD
Crizotinib—EPHA3—central nervous system—attention deficit hyperactivity disorder	0.00211	0.00363	CbGeAlD
Crizotinib—ACVR1B—central nervous system—attention deficit hyperactivity disorder	0.00211	0.00363	CbGeAlD
Crizotinib—PRKD3—brain—attention deficit hyperactivity disorder	0.0021	0.0036	CbGeAlD
Crizotinib—EPHA6—nervous system—attention deficit hyperactivity disorder	0.00209	0.00359	CbGeAlD
Crizotinib—JAK3—nervous system—attention deficit hyperactivity disorder	0.00209	0.00359	CbGeAlD
Crizotinib—DCLK1—nervous system—attention deficit hyperactivity disorder	0.00208	0.00357	CbGeAlD
Crizotinib—RPS6KB1—cardiovascular system—attention deficit hyperactivity disorder	0.00207	0.00356	CbGeAlD
Crizotinib—ACVR1B—cerebellum—attention deficit hyperactivity disorder	0.00206	0.00354	CbGeAlD
Crizotinib—FGR—cardiovascular system—attention deficit hyperactivity disorder	0.00206	0.00354	CbGeAlD
Crizotinib—STK4—nervous system—attention deficit hyperactivity disorder	0.00205	0.00353	CbGeAlD
Crizotinib—AXL—cardiovascular system—attention deficit hyperactivity disorder	0.00205	0.00353	CbGeAlD
Crizotinib—DSTYK—brain—attention deficit hyperactivity disorder	0.00205	0.00352	CbGeAlD
Crizotinib—TAOK3—forebrain—attention deficit hyperactivity disorder	0.00202	0.00348	CbGeAlD
Crizotinib—EPHA6—central nervous system—attention deficit hyperactivity disorder	0.00201	0.00346	CbGeAlD
Crizotinib—JAK3—central nervous system—attention deficit hyperactivity disorder	0.00201	0.00346	CbGeAlD
Crizotinib—ACVR1—midbrain—attention deficit hyperactivity disorder	0.00201	0.00345	CbGeAlD
Crizotinib—MAP3K12—midbrain—attention deficit hyperactivity disorder	0.00201	0.00345	CbGeAlD
Crizotinib—DCLK1—central nervous system—attention deficit hyperactivity disorder	0.002	0.00344	CbGeAlD
Crizotinib—LTK—brain—attention deficit hyperactivity disorder	0.002	0.00344	CbGeAlD
Crizotinib—CASK—brain—attention deficit hyperactivity disorder	0.002	0.00344	CbGeAlD
Crizotinib—STK4—central nervous system—attention deficit hyperactivity disorder	0.00198	0.0034	CbGeAlD
Crizotinib—SRC—forebrain—attention deficit hyperactivity disorder	0.00197	0.00339	CbGeAlD
Crizotinib—JAK3—cerebellum—attention deficit hyperactivity disorder	0.00197	0.00338	CbGeAlD
Crizotinib—STK35—midbrain—attention deficit hyperactivity disorder	0.00197	0.00338	CbGeAlD
Crizotinib—EPHB4—cardiovascular system—attention deficit hyperactivity disorder	0.00196	0.00337	CbGeAlD
Crizotinib—DCLK1—cerebellum—attention deficit hyperactivity disorder	0.00196	0.00336	CbGeAlD
Crizotinib—JAK2—cardiovascular system—attention deficit hyperactivity disorder	0.00195	0.00335	CbGeAlD
Crizotinib—EPHA5—nervous system—attention deficit hyperactivity disorder	0.00194	0.00333	CbGeAlD
Crizotinib—ALK—nervous system—attention deficit hyperactivity disorder	0.00194	0.00333	CbGeAlD
Crizotinib—FER—nervous system—attention deficit hyperactivity disorder	0.00194	0.00333	CbGeAlD
Crizotinib—TYRO3—nervous system—attention deficit hyperactivity disorder	0.00194	0.00333	CbGeAlD
Crizotinib—MAPK7—brain—attention deficit hyperactivity disorder	0.00194	0.00333	CbGeAlD
Crizotinib—STK4—cerebellum—attention deficit hyperactivity disorder	0.00193	0.00332	CbGeAlD
Crizotinib—LYN—nervous system—attention deficit hyperactivity disorder	0.00193	0.00332	CbGeAlD
Crizotinib—EPHA2—cardiovascular system—attention deficit hyperactivity disorder	0.00192	0.00331	CbGeAlD
Crizotinib—EPHA8—brain—attention deficit hyperactivity disorder	0.00192	0.00329	CbGeAlD
Crizotinib—FES—brain—attention deficit hyperactivity disorder	0.00192	0.00329	CbGeAlD
Crizotinib—BMPR1B—nervous system—attention deficit hyperactivity disorder	0.0019	0.00327	CbGeAlD
Crizotinib—MAP3K19—nervous system—attention deficit hyperactivity disorder	0.0019	0.00327	CbGeAlD
Crizotinib—BMP2K—midbrain—attention deficit hyperactivity disorder	0.00189	0.00325	CbGeAlD
Crizotinib—TEK—cardiovascular system—attention deficit hyperactivity disorder	0.00188	0.00323	CbGeAlD
Crizotinib—MAP3K3—cardiovascular system—attention deficit hyperactivity disorder	0.00188	0.00323	CbGeAlD
Crizotinib—FER—central nervous system—attention deficit hyperactivity disorder	0.00187	0.00321	CbGeAlD
Crizotinib—TYRO3—central nervous system—attention deficit hyperactivity disorder	0.00187	0.00321	CbGeAlD
Crizotinib—ALK—central nervous system—attention deficit hyperactivity disorder	0.00187	0.00321	CbGeAlD
Crizotinib—EPHA5—central nervous system—attention deficit hyperactivity disorder	0.00187	0.00321	CbGeAlD
Crizotinib—TNK2—nervous system—attention deficit hyperactivity disorder	0.00187	0.0032	CbGeAlD
Crizotinib—IGF1R—nervous system—attention deficit hyperactivity disorder	0.00187	0.0032	CbGeAlD
Crizotinib—LYN—central nervous system—attention deficit hyperactivity disorder	0.00186	0.00319	CbGeAlD
Crizotinib—BMPR1B—central nervous system—attention deficit hyperactivity disorder	0.00183	0.00314	CbGeAlD
Crizotinib—MAP3K19—central nervous system—attention deficit hyperactivity disorder	0.00183	0.00314	CbGeAlD
Crizotinib—TYRO3—cerebellum—attention deficit hyperactivity disorder	0.00183	0.00314	CbGeAlD
Crizotinib—FER—cerebellum—attention deficit hyperactivity disorder	0.00183	0.00314	CbGeAlD
Crizotinib—EPHA5—cerebellum—attention deficit hyperactivity disorder	0.00183	0.00314	CbGeAlD
Crizotinib—TIE1—nervous system—attention deficit hyperactivity disorder	0.00181	0.00312	CbGeAlD
Crizotinib—MET—brain—attention deficit hyperactivity disorder	0.00181	0.00311	CbGeAlD
Crizotinib—RIPK2—midbrain—attention deficit hyperactivity disorder	0.00181	0.00311	CbGeAlD
Crizotinib—TNK1—cerebellum—attention deficit hyperactivity disorder	0.00181	0.0031	CbGeAlD
Crizotinib—TNK2—central nervous system—attention deficit hyperactivity disorder	0.0018	0.00308	CbGeAlD
Crizotinib—IGF1R—central nervous system—attention deficit hyperactivity disorder	0.0018	0.00308	CbGeAlD
Crizotinib—BMPR1B—cerebellum—attention deficit hyperactivity disorder	0.00179	0.00307	CbGeAlD
Crizotinib—CSF1R—forebrain—attention deficit hyperactivity disorder	0.00177	0.00304	CbGeAlD
Crizotinib—AURKA—nervous system—attention deficit hyperactivity disorder	0.00177	0.00304	CbGeAlD
Crizotinib—TNK2—cerebellum—attention deficit hyperactivity disorder	0.00176	0.00301	CbGeAlD
Crizotinib—IGF1R—cerebellum—attention deficit hyperactivity disorder	0.00176	0.00301	CbGeAlD
Crizotinib—CDK7—brain—attention deficit hyperactivity disorder	0.00175	0.00301	CbGeAlD
Crizotinib—TESK1—nervous system—attention deficit hyperactivity disorder	0.00175	0.00301	CbGeAlD
Crizotinib—TIE1—central nervous system—attention deficit hyperactivity disorder	0.00175	0.003	CbGeAlD
Crizotinib—TAOK2—brain—attention deficit hyperactivity disorder	0.00174	0.00299	CbGeAlD
Crizotinib—MAP4K2—cerebellum—attention deficit hyperactivity disorder	0.00173	0.00297	CbGeAlD
Crizotinib—STK10—cardiovascular system—attention deficit hyperactivity disorder	0.00172	0.00295	CbGeAlD
Crizotinib—TAOK3—cardiovascular system—attention deficit hyperactivity disorder	0.00171	0.00294	CbGeAlD
Crizotinib—TIE1—cerebellum—attention deficit hyperactivity disorder	0.00171	0.00293	CbGeAlD
Crizotinib—STK3—cerebellum—attention deficit hyperactivity disorder	0.00171	0.00293	CbGeAlD
Crizotinib—MERTK—nervous system—attention deficit hyperactivity disorder	0.00171	0.00293	CbGeAlD
Crizotinib—AURKA—central nervous system—attention deficit hyperactivity disorder	0.0017	0.00292	CbGeAlD
Crizotinib—TESK1—central nervous system—attention deficit hyperactivity disorder	0.00169	0.0029	CbGeAlD
Crizotinib—PTK2—midbrain—attention deficit hyperactivity disorder	0.00168	0.00289	CbGeAlD
Crizotinib—TBK1—midbrain—attention deficit hyperactivity disorder	0.00168	0.00289	CbGeAlD
Crizotinib—EPHA3—brain—attention deficit hyperactivity disorder	0.00168	0.00288	CbGeAlD
Crizotinib—ACVR1B—brain—attention deficit hyperactivity disorder	0.00168	0.00288	CbGeAlD
Crizotinib—TYK2—midbrain—attention deficit hyperactivity disorder	0.00167	0.00287	CbGeAlD
Crizotinib—SRC—cardiovascular system—attention deficit hyperactivity disorder	0.00167	0.00287	CbGeAlD
Crizotinib—LIMK2—nervous system—attention deficit hyperactivity disorder	0.00167	0.00287	CbGeAlD
Crizotinib—IRAK1—midbrain—attention deficit hyperactivity disorder	0.00165	0.00283	CbGeAlD
Crizotinib—MAP3K12—nervous system—attention deficit hyperactivity disorder	0.00165	0.00283	CbGeAlD
Crizotinib—ACVR1—nervous system—attention deficit hyperactivity disorder	0.00165	0.00283	CbGeAlD
Crizotinib—TESK1—cerebellum—attention deficit hyperactivity disorder	0.00165	0.00283	CbGeAlD
Crizotinib—MERTK—central nervous system—attention deficit hyperactivity disorder	0.00164	0.00282	CbGeAlD
Crizotinib—RPS6KB1—midbrain—attention deficit hyperactivity disorder	0.00162	0.00278	CbGeAlD
Crizotinib—STK35—nervous system—attention deficit hyperactivity disorder	0.00162	0.00278	CbGeAlD
Crizotinib—LIMK2—central nervous system—attention deficit hyperactivity disorder	0.00161	0.00276	CbGeAlD
Crizotinib—MERTK—cerebellum—attention deficit hyperactivity disorder	0.00161	0.00276	CbGeAlD
Crizotinib—AXL—midbrain—attention deficit hyperactivity disorder	0.0016	0.00275	CbGeAlD
Crizotinib—JAK3—brain—attention deficit hyperactivity disorder	0.0016	0.00275	CbGeAlD
Crizotinib—EPHA6—brain—attention deficit hyperactivity disorder	0.0016	0.00275	CbGeAlD
Crizotinib—DCLK1—brain—attention deficit hyperactivity disorder	0.00159	0.00273	CbGeAlD
Crizotinib—MAP3K12—central nervous system—attention deficit hyperactivity disorder	0.00159	0.00273	CbGeAlD
Crizotinib—ACVR1—central nervous system—attention deficit hyperactivity disorder	0.00159	0.00273	CbGeAlD
Crizotinib—PLK4—brain—attention deficit hyperactivity disorder	0.00158	0.00271	CbGeAlD
Crizotinib—STK4—brain—attention deficit hyperactivity disorder	0.00157	0.0027	CbGeAlD
Crizotinib—LIMK2—cerebellum—attention deficit hyperactivity disorder	0.00157	0.0027	CbGeAlD
Crizotinib—NUAK2—cerebellum—attention deficit hyperactivity disorder	0.00156	0.00269	CbGeAlD
Crizotinib—STK35—central nervous system—attention deficit hyperactivity disorder	0.00156	0.00267	CbGeAlD
Crizotinib—BMP2K—nervous system—attention deficit hyperactivity disorder	0.00156	0.00267	CbGeAlD
Crizotinib—FLT3—cerebellum—attention deficit hyperactivity disorder	0.00155	0.00267	CbGeAlD
Crizotinib—ACVR1—cerebellum—attention deficit hyperactivity disorder	0.00155	0.00267	CbGeAlD
Crizotinib—MAP3K12—cerebellum—attention deficit hyperactivity disorder	0.00155	0.00267	CbGeAlD
Crizotinib—SLK—midbrain—attention deficit hyperactivity disorder	0.00154	0.00265	CbGeAlD
Crizotinib—EPHB4—midbrain—attention deficit hyperactivity disorder	0.00153	0.00263	CbGeAlD
Crizotinib—STK35—cerebellum—attention deficit hyperactivity disorder	0.00152	0.00261	CbGeAlD
Crizotinib—PTK2B—nervous system—attention deficit hyperactivity disorder	0.0015	0.00258	CbGeAlD
Crizotinib—BMP2K—central nervous system—attention deficit hyperactivity disorder	0.0015	0.00257	CbGeAlD
Crizotinib—CSF1R—cardiovascular system—attention deficit hyperactivity disorder	0.0015	0.00257	CbGeAlD
Crizotinib—ALK—brain—attention deficit hyperactivity disorder	0.00148	0.00255	CbGeAlD
Crizotinib—TYRO3—brain—attention deficit hyperactivity disorder	0.00148	0.00255	CbGeAlD
Crizotinib—FER—brain—attention deficit hyperactivity disorder	0.00148	0.00255	CbGeAlD
Crizotinib—EPHA5—brain—attention deficit hyperactivity disorder	0.00148	0.00255	CbGeAlD
Crizotinib—ABL2—cerebellum—attention deficit hyperactivity disorder	0.00148	0.00255	CbGeAlD
Crizotinib—LYN—brain—attention deficit hyperactivity disorder	0.00148	0.00253	CbGeAlD
Crizotinib—TNK1—brain—attention deficit hyperactivity disorder	0.00147	0.00252	CbGeAlD
Crizotinib—MAP4K5—midbrain—attention deficit hyperactivity disorder	0.00147	0.00252	CbGeAlD
Crizotinib—MAP3K3—midbrain—attention deficit hyperactivity disorder	0.00147	0.00252	CbGeAlD
Crizotinib—TEK—midbrain—attention deficit hyperactivity disorder	0.00147	0.00252	CbGeAlD
Crizotinib—BMP2K—cerebellum—attention deficit hyperactivity disorder	0.00146	0.00252	CbGeAlD
Crizotinib—MAP3K19—brain—attention deficit hyperactivity disorder	0.00145	0.0025	CbGeAlD
Crizotinib—MAP4K1—brain—attention deficit hyperactivity disorder	0.00145	0.0025	CbGeAlD
Crizotinib—BMPR1B—brain—attention deficit hyperactivity disorder	0.00145	0.0025	CbGeAlD
Crizotinib—PTK2B—central nervous system—attention deficit hyperactivity disorder	0.00145	0.00249	CbGeAlD
Crizotinib—EPHA4—nervous system—attention deficit hyperactivity disorder	0.00144	0.00248	CbGeAlD
Crizotinib—TNK2—brain—attention deficit hyperactivity disorder	0.00143	0.00245	CbGeAlD
Crizotinib—IGF1R—brain—attention deficit hyperactivity disorder	0.00143	0.00245	CbGeAlD
Crizotinib—PTK2B—cerebellum—attention deficit hyperactivity disorder	0.00141	0.00243	CbGeAlD
Crizotinib—MAP3K2—nervous system—attention deficit hyperactivity disorder	0.00141	0.00243	CbGeAlD
Crizotinib—MAP4K2—brain—attention deficit hyperactivity disorder	0.00141	0.00241	CbGeAlD
Crizotinib—RIPK2—cerebellum—attention deficit hyperactivity disorder	0.0014	0.00241	CbGeAlD
Crizotinib—EPHB6—midbrain—attention deficit hyperactivity disorder	0.0014	0.00241	CbGeAlD
Crizotinib—EPHA4—central nervous system—attention deficit hyperactivity disorder	0.00139	0.00238	CbGeAlD
Crizotinib—TIE1—brain—attention deficit hyperactivity disorder	0.00139	0.00238	CbGeAlD
Crizotinib—STK3—brain—attention deficit hyperactivity disorder	0.00139	0.00238	CbGeAlD
Crizotinib—PTK2—nervous system—attention deficit hyperactivity disorder	0.00138	0.00238	CbGeAlD
Crizotinib—TBK1—nervous system—attention deficit hyperactivity disorder	0.00138	0.00238	CbGeAlD
Crizotinib—TYK2—nervous system—attention deficit hyperactivity disorder	0.00137	0.00236	CbGeAlD
Crizotinib—MAP3K2—central nervous system—attention deficit hyperactivity disorder	0.00136	0.00234	CbGeAlD
Crizotinib—EPHA4—cerebellum—attention deficit hyperactivity disorder	0.00136	0.00233	CbGeAlD
Crizotinib—YES1—midbrain—attention deficit hyperactivity disorder	0.00135	0.00233	CbGeAlD
Crizotinib—AURKA—brain—attention deficit hyperactivity disorder	0.00135	0.00232	CbGeAlD
Crizotinib—TESK1—brain—attention deficit hyperactivity disorder	0.00134	0.0023	CbGeAlD
Crizotinib—TAOK3—midbrain—attention deficit hyperactivity disorder	0.00134	0.0023	CbGeAlD
Crizotinib—PTK2—central nervous system—attention deficit hyperactivity disorder	0.00133	0.00229	CbGeAlD
Crizotinib—TBK1—central nervous system—attention deficit hyperactivity disorder	0.00133	0.00229	CbGeAlD
Crizotinib—RPS6KB1—nervous system—attention deficit hyperactivity disorder	0.00133	0.00229	CbGeAlD
Crizotinib—MAP3K2—cerebellum—attention deficit hyperactivity disorder	0.00133	0.00228	CbGeAlD
Crizotinib—TYK2—central nervous system—attention deficit hyperactivity disorder	0.00132	0.00227	CbGeAlD
Crizotinib—FGR—nervous system—attention deficit hyperactivity disorder	0.00132	0.00227	CbGeAlD
Crizotinib—AXL—nervous system—attention deficit hyperactivity disorder	0.00132	0.00226	CbGeAlD
Crizotinib—MERTK—brain—attention deficit hyperactivity disorder	0.0013	0.00224	CbGeAlD
Crizotinib—PTK2—cerebellum—attention deficit hyperactivity disorder	0.0013	0.00224	CbGeAlD
Crizotinib—TBK1—cerebellum—attention deficit hyperactivity disorder	0.0013	0.00224	CbGeAlD
Crizotinib—TYK2—cerebellum—attention deficit hyperactivity disorder	0.00129	0.00222	CbGeAlD
Crizotinib—RPS6KB1—central nervous system—attention deficit hyperactivity disorder	0.00128	0.0022	CbGeAlD
Crizotinib—IRAK1—cerebellum—attention deficit hyperactivity disorder	0.00128	0.00219	CbGeAlD
Crizotinib—LIMK2—brain—attention deficit hyperactivity disorder	0.00128	0.00219	CbGeAlD
Crizotinib—FGR—central nervous system—attention deficit hyperactivity disorder	0.00127	0.00219	CbGeAlD
Crizotinib—NUAK2—brain—attention deficit hyperactivity disorder	0.00127	0.00218	CbGeAlD
Crizotinib—AXL—central nervous system—attention deficit hyperactivity disorder	0.00127	0.00218	CbGeAlD
Crizotinib—MAP3K12—brain—attention deficit hyperactivity disorder	0.00126	0.00217	CbGeAlD
Crizotinib—ACVR1—brain—attention deficit hyperactivity disorder	0.00126	0.00217	CbGeAlD
Crizotinib—RPS6KB1—cerebellum—attention deficit hyperactivity disorder	0.00125	0.00215	CbGeAlD
Crizotinib—JAK2—nervous system—attention deficit hyperactivity disorder	0.00125	0.00215	CbGeAlD
Crizotinib—AXL—cerebellum—attention deficit hyperactivity disorder	0.00124	0.00213	CbGeAlD
Crizotinib—STK35—brain—attention deficit hyperactivity disorder	0.00124	0.00212	CbGeAlD
Crizotinib—EPHA2—nervous system—attention deficit hyperactivity disorder	0.00124	0.00212	CbGeAlD
Crizotinib—MAP4K5—nervous system—attention deficit hyperactivity disorder	0.00121	0.00207	CbGeAlD
Crizotinib—MAP3K3—nervous system—attention deficit hyperactivity disorder	0.00121	0.00207	CbGeAlD
Crizotinib—TEK—nervous system—attention deficit hyperactivity disorder	0.00121	0.00207	CbGeAlD
Crizotinib—ABL2—brain—attention deficit hyperactivity disorder	0.0012	0.00207	CbGeAlD
Crizotinib—JAK2—central nervous system—attention deficit hyperactivity disorder	0.0012	0.00207	CbGeAlD
Crizotinib—SLK—cerebellum—attention deficit hyperactivity disorder	0.00119	0.00205	CbGeAlD
Crizotinib—EPHA2—central nervous system—attention deficit hyperactivity disorder	0.00119	0.00204	CbGeAlD
Crizotinib—BMP2K—brain—attention deficit hyperactivity disorder	0.00119	0.00204	CbGeAlD
Crizotinib—EPHB4—cerebellum—attention deficit hyperactivity disorder	0.00119	0.00204	CbGeAlD
Crizotinib—ABL1—cardiovascular system—attention deficit hyperactivity disorder	0.00118	0.00203	CbGeAlD
Crizotinib—JAK2—cerebellum—attention deficit hyperactivity disorder	0.00118	0.00202	CbGeAlD
Crizotinib—CSF1R—midbrain—attention deficit hyperactivity disorder	0.00117	0.00201	CbGeAlD
Crizotinib—MAP4K5—central nervous system—attention deficit hyperactivity disorder	0.00116	0.00199	CbGeAlD
Crizotinib—MAP3K3—central nervous system—attention deficit hyperactivity disorder	0.00116	0.00199	CbGeAlD
Crizotinib—TEK—central nervous system—attention deficit hyperactivity disorder	0.00116	0.00199	CbGeAlD
Crizotinib—EPHB6—nervous system—attention deficit hyperactivity disorder	0.00115	0.00198	CbGeAlD
Crizotinib—PTK2B—brain—attention deficit hyperactivity disorder	0.00115	0.00197	CbGeAlD
Crizotinib—RIPK2—brain—attention deficit hyperactivity disorder	0.00114	0.00196	CbGeAlD
Crizotinib—MAP4K5—cerebellum—attention deficit hyperactivity disorder	0.00113	0.00195	CbGeAlD
Crizotinib—MAP3K3—cerebellum—attention deficit hyperactivity disorder	0.00113	0.00195	CbGeAlD
Crizotinib—TEK—cerebellum—attention deficit hyperactivity disorder	0.00113	0.00195	CbGeAlD
Crizotinib—YES1—nervous system—attention deficit hyperactivity disorder	0.00111	0.00191	CbGeAlD
Crizotinib—EPHB6—central nervous system—attention deficit hyperactivity disorder	0.00111	0.00191	CbGeAlD
Crizotinib—STK10—nervous system—attention deficit hyperactivity disorder	0.0011	0.00189	CbGeAlD
Crizotinib—EPHA4—brain—attention deficit hyperactivity disorder	0.0011	0.00189	CbGeAlD
Crizotinib—TAOK3—nervous system—attention deficit hyperactivity disorder	0.0011	0.00189	CbGeAlD
Crizotinib—EPHB6—cerebellum—attention deficit hyperactivity disorder	0.00108	0.00186	CbGeAlD
Crizotinib—MAP3K2—brain—attention deficit hyperactivity disorder	0.00108	0.00186	CbGeAlD
Crizotinib—YES1—central nervous system—attention deficit hyperactivity disorder	0.00107	0.00184	CbGeAlD
Crizotinib—SRC—nervous system—attention deficit hyperactivity disorder	0.00107	0.00184	CbGeAlD
Crizotinib—STK10—central nervous system—attention deficit hyperactivity disorder	0.00106	0.00182	CbGeAlD
Crizotinib—TAOK3—central nervous system—attention deficit hyperactivity disorder	0.00106	0.00182	CbGeAlD
Crizotinib—PTK2—brain—attention deficit hyperactivity disorder	0.00106	0.00182	CbGeAlD
Crizotinib—TBK1—brain—attention deficit hyperactivity disorder	0.00106	0.00182	CbGeAlD
Crizotinib—TYK2—brain—attention deficit hyperactivity disorder	0.00105	0.0018	CbGeAlD
Crizotinib—YES1—cerebellum—attention deficit hyperactivity disorder	0.00105	0.0018	CbGeAlD
Crizotinib—STK10—cerebellum—attention deficit hyperactivity disorder	0.00104	0.00178	CbGeAlD
Crizotinib—IRAK1—brain—attention deficit hyperactivity disorder	0.00104	0.00178	CbGeAlD
Crizotinib—TAOK3—cerebellum—attention deficit hyperactivity disorder	0.00103	0.00178	CbGeAlD
Crizotinib—SRC—central nervous system—attention deficit hyperactivity disorder	0.00103	0.00177	CbGeAlD
Crizotinib—RPS6KB1—brain—attention deficit hyperactivity disorder	0.00102	0.00175	CbGeAlD
Crizotinib—FGR—brain—attention deficit hyperactivity disorder	0.00101	0.00174	CbGeAlD
Crizotinib—SRC—cerebellum—attention deficit hyperactivity disorder	0.00101	0.00173	CbGeAlD
Crizotinib—AXL—brain—attention deficit hyperactivity disorder	0.00101	0.00173	CbGeAlD
Crizotinib—SLK—brain—attention deficit hyperactivity disorder	0.00097	0.00167	CbGeAlD
Crizotinib—EPHB4—brain—attention deficit hyperactivity disorder	0.000963	0.00165	CbGeAlD
Crizotinib—CSF1R—nervous system—attention deficit hyperactivity disorder	0.000962	0.00165	CbGeAlD
Crizotinib—JAK2—brain—attention deficit hyperactivity disorder	0.000956	0.00164	CbGeAlD
Crizotinib—EPHA2—brain—attention deficit hyperactivity disorder	0.000945	0.00162	CbGeAlD
Crizotinib—CSF1R—central nervous system—attention deficit hyperactivity disorder	0.000926	0.00159	CbGeAlD
Crizotinib—ABL1—midbrain—attention deficit hyperactivity disorder	0.000925	0.00159	CbGeAlD
Crizotinib—MAP4K5—brain—attention deficit hyperactivity disorder	0.000922	0.00158	CbGeAlD
Crizotinib—TEK—brain—attention deficit hyperactivity disorder	0.000922	0.00158	CbGeAlD
Crizotinib—MAP3K3—brain—attention deficit hyperactivity disorder	0.000922	0.00158	CbGeAlD
Crizotinib—CSF1R—cerebellum—attention deficit hyperactivity disorder	0.000905	0.00155	CbGeAlD
Crizotinib—EPHB6—brain—attention deficit hyperactivity disorder	0.000881	0.00151	CbGeAlD
Crizotinib—YES1—brain—attention deficit hyperactivity disorder	0.000851	0.00146	CbGeAlD
Crizotinib—STK10—brain—attention deficit hyperactivity disorder	0.000843	0.00145	CbGeAlD
Crizotinib—TAOK3—brain—attention deficit hyperactivity disorder	0.00084	0.00144	CbGeAlD
Crizotinib—SRC—brain—attention deficit hyperactivity disorder	0.000819	0.00141	CbGeAlD
Crizotinib—ABL1—nervous system—attention deficit hyperactivity disorder	0.00076	0.00131	CbGeAlD
Crizotinib—CSF1R—brain—attention deficit hyperactivity disorder	0.000735	0.00126	CbGeAlD
Crizotinib—ABL1—central nervous system—attention deficit hyperactivity disorder	0.000732	0.00126	CbGeAlD
Crizotinib—ABL1—cerebellum—attention deficit hyperactivity disorder	0.000715	0.00123	CbGeAlD
Crizotinib—ABL1—brain—attention deficit hyperactivity disorder	0.000581	0.000998	CbGeAlD
Crizotinib—ABCB1—forebrain—attention deficit hyperactivity disorder	0.000435	0.000748	CbGeAlD
Crizotinib—ABCB1—cardiovascular system—attention deficit hyperactivity disorder	0.000368	0.000632	CbGeAlD
Crizotinib—CYP3A4—nervous system—attention deficit hyperactivity disorder	0.000334	0.000573	CbGeAlD
Crizotinib—CYP3A4—central nervous system—attention deficit hyperactivity disorder	0.000322	0.000552	CbGeAlD
Crizotinib—ABCB1—midbrain—attention deficit hyperactivity disorder	0.000288	0.000494	CbGeAlD
Crizotinib—ABCB1—nervous system—attention deficit hyperactivity disorder	0.000236	0.000406	CbGeAlD
Crizotinib—ABCB1—central nervous system—attention deficit hyperactivity disorder	0.000228	0.000391	CbGeAlD
Crizotinib—ABCB1—cerebellum—attention deficit hyperactivity disorder	0.000222	0.000382	CbGeAlD
Crizotinib—ABCB1—brain—attention deficit hyperactivity disorder	0.000181	0.00031	CbGeAlD
Crizotinib—TXK—Immune System—EP300—attention deficit hyperactivity disorder	9.49e-05	0.000227	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	9.32e-05	0.000223	CbGpPWpGaD
Crizotinib—JAK2—GPCR downstream signaling—HTR1B—attention deficit hyperactivity disorder	9.28e-05	0.000222	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	9.22e-05	0.000221	CbGpPWpGaD
Crizotinib—JAK3—Hemostasis—EP300—attention deficit hyperactivity disorder	9.22e-05	0.000221	CbGpPWpGaD
Crizotinib—TBK1—Innate Immune System—EP300—attention deficit hyperactivity disorder	9.18e-05	0.00022	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	9.16e-05	0.000219	CbGpPWpGaD
Crizotinib—CDK7—Cell Cycle, Mitotic—EP300—attention deficit hyperactivity disorder	9.09e-05	0.000218	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	9.09e-05	0.000218	CbGpPWpGaD
Crizotinib—TYK2—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	9.06e-05	0.000217	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	9.04e-05	0.000217	CbGpPWpGaD
Crizotinib—FES—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	9.03e-05	0.000216	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	8.97e-05	0.000215	CbGpPWpGaD
Crizotinib—SRC—Immune System—POLR3A—attention deficit hyperactivity disorder	8.88e-05	0.000213	CbGpPWpGaD
Crizotinib—STK4—Signaling Pathways—EP300—attention deficit hyperactivity disorder	8.86e-05	0.000212	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	8.78e-05	0.00021	CbGpPWpGaD
Crizotinib—JAK2—Chromatin modifying enzymes—EP300—attention deficit hyperactivity disorder	8.74e-05	0.000209	CbGpPWpGaD
Crizotinib—TYK2—Disease—SNAP25—attention deficit hyperactivity disorder	8.72e-05	0.000209	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	8.7e-05	0.000208	CbGpPWpGaD
Crizotinib—JAK2—GPCR downstream signaling—DRD1—attention deficit hyperactivity disorder	8.63e-05	0.000207	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	8.61e-05	0.000206	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	8.57e-05	0.000205	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—STUB1—attention deficit hyperactivity disorder	8.55e-05	0.000205	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	8.45e-05	0.000202	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	8.44e-05	0.000202	CbGpPWpGaD
Crizotinib—JAK2—Signaling by GPCR—HTR1B—attention deficit hyperactivity disorder	8.43e-05	0.000202	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	8.43e-05	0.000202	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	8.39e-05	0.000201	CbGpPWpGaD
Crizotinib—JAK2—GPCR downstream signaling—DRD3—attention deficit hyperactivity disorder	8.36e-05	0.0002	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	8.3e-05	0.000199	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	8.28e-05	0.000198	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	8.22e-05	0.000197	CbGpPWpGaD
Crizotinib—JAK2—GPCR downstream signaling—ADRA2A—attention deficit hyperactivity disorder	8.22e-05	0.000197	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	8.18e-05	0.000196	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	8.17e-05	0.000195	CbGpPWpGaD
Crizotinib—IGF1R—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	8.16e-05	0.000195	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	8.16e-05	0.000195	CbGpPWpGaD
Crizotinib—CDK7—Cell Cycle—EP300—attention deficit hyperactivity disorder	8.13e-05	0.000195	CbGpPWpGaD
Crizotinib—JAK2—GPCR downstream signaling—DRD4—attention deficit hyperactivity disorder	8.12e-05	0.000194	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	8.09e-05	0.000194	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	8.06e-05	0.000193	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	8.06e-05	0.000193	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	8.04e-05	0.000193	CbGpPWpGaD
Crizotinib—MAPK7—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	7.99e-05	0.000191	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	7.95e-05	0.00019	CbGpPWpGaD
Crizotinib—FGR—Hemostasis—EP300—attention deficit hyperactivity disorder	7.88e-05	0.000189	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	7.84e-05	0.000188	CbGpPWpGaD
Crizotinib—JAK2—Signaling by GPCR—DRD1—attention deficit hyperactivity disorder	7.84e-05	0.000188	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	7.83e-05	0.000188	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	7.74e-05	0.000185	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	7.7e-05	0.000184	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	7.6e-05	0.000182	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	7.6e-05	0.000182	CbGpPWpGaD
Crizotinib—JAK2—Signaling by GPCR—DRD3—attention deficit hyperactivity disorder	7.59e-05	0.000182	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—STUB1—attention deficit hyperactivity disorder	7.57e-05	0.000181	CbGpPWpGaD
Crizotinib—JAK2—GPCR downstream signaling—DRD2—attention deficit hyperactivity disorder	7.56e-05	0.000181	CbGpPWpGaD
Crizotinib—PRKD1—Metabolism—EP300—attention deficit hyperactivity disorder	7.55e-05	0.000181	CbGpPWpGaD
Crizotinib—STK3—Signaling Pathways—EP300—attention deficit hyperactivity disorder	7.53e-05	0.00018	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	7.52e-05	0.00018	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	7.51e-05	0.00018	CbGpPWpGaD
Crizotinib—SRC—Integrated Pancreatic Cancer Pathway—EP300—attention deficit hyperactivity disorder	7.5e-05	0.00018	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	7.47e-05	0.000179	CbGpPWpGaD
Crizotinib—JAK2—Signaling by GPCR—ADRA2A—attention deficit hyperactivity disorder	7.46e-05	0.000179	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	7.4e-05	0.000177	CbGpPWpGaD
Crizotinib—RIPK2—Innate Immune System—EP300—attention deficit hyperactivity disorder	7.4e-05	0.000177	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	7.37e-05	0.000177	CbGpPWpGaD
Crizotinib—JAK2—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	7.37e-05	0.000176	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	7.35e-05	0.000176	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	7.24e-05	0.000173	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	7.2e-05	0.000172	CbGpPWpGaD
Crizotinib—IKBKE—Immune System—EP300—attention deficit hyperactivity disorder	7.19e-05	0.000172	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	7.14e-05	0.000171	CbGpPWpGaD
Crizotinib—FGR—Innate Immune System—EP300—attention deficit hyperactivity disorder	7.09e-05	0.00017	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	7.08e-05	0.00017	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	7.06e-05	0.000169	CbGpPWpGaD
Crizotinib—CYP3A4—Biological oxidations—COMT—attention deficit hyperactivity disorder	6.94e-05	0.000166	CbGpPWpGaD
Crizotinib—CYP3A4—Biological oxidations—MAOA—attention deficit hyperactivity disorder	6.89e-05	0.000165	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	6.87e-05	0.000164	CbGpPWpGaD
Crizotinib—JAK2—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	6.87e-05	0.000164	CbGpPWpGaD
Crizotinib—CYP3A4—Metapathway biotransformation—COMT—attention deficit hyperactivity disorder	6.84e-05	0.000164	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	6.77e-05	0.000162	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	6.73e-05	0.000161	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	6.64e-05	0.000159	CbGpPWpGaD
Crizotinib—JAK2—Disease—SNAP25—attention deficit hyperactivity disorder	6.61e-05	0.000158	CbGpPWpGaD
Crizotinib—PTK2—Developmental Biology—EP300—attention deficit hyperactivity disorder	6.58e-05	0.000157	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	6.57e-05	0.000157	CbGpPWpGaD
Crizotinib—MAPK7—Immune System—EP300—attention deficit hyperactivity disorder	6.55e-05	0.000157	CbGpPWpGaD
Crizotinib—LIMK1—Immune System—EP300—attention deficit hyperactivity disorder	6.55e-05	0.000157	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	6.52e-05	0.000156	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	6.51e-05	0.000156	CbGpPWpGaD
Crizotinib—YES1—Developmental Biology—EP300—attention deficit hyperactivity disorder	6.48e-05	0.000155	CbGpPWpGaD
Crizotinib—PTK2—Hemostasis—EP300—attention deficit hyperactivity disorder	6.45e-05	0.000154	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	6.43e-05	0.000154	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	6.41e-05	0.000153	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	6.37e-05	0.000153	CbGpPWpGaD
Crizotinib—YES1—Hemostasis—EP300—attention deficit hyperactivity disorder	6.36e-05	0.000152	CbGpPWpGaD
Crizotinib—TYK2—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	6.34e-05	0.000152	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	6.33e-05	0.000151	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	6.32e-05	0.000151	CbGpPWpGaD
Crizotinib—ACVR1B—Signaling Pathways—EP300—attention deficit hyperactivity disorder	6.31e-05	0.000151	CbGpPWpGaD
Crizotinib—FER—Signaling Pathways—EP300—attention deficit hyperactivity disorder	6.31e-05	0.000151	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	6.29e-05	0.000151	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	6.25e-05	0.00015	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	6.24e-05	0.000149	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	6.11e-05	0.000146	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—ADRA2C—attention deficit hyperactivity disorder	6.1e-05	0.000146	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	6.1e-05	0.000146	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	6.09e-05	0.000146	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	5.99e-05	0.000143	CbGpPWpGaD
Crizotinib—AXL—Signaling Pathways—EP300—attention deficit hyperactivity disorder	5.98e-05	0.000143	CbGpPWpGaD
Crizotinib—TYK2—Developmental Biology—EP300—attention deficit hyperactivity disorder	5.97e-05	0.000143	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	5.92e-05	0.000142	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	5.92e-05	0.000142	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	5.9e-05	0.000141	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	5.89e-05	0.000141	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	5.82e-05	0.000139	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	5.81e-05	0.000139	CbGpPWpGaD
Crizotinib—PTK2—Innate Immune System—EP300—attention deficit hyperactivity disorder	5.81e-05	0.000139	CbGpPWpGaD
Crizotinib—LCK—Disease—SNAP25—attention deficit hyperactivity disorder	5.79e-05	0.000139	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	5.74e-05	0.000138	CbGpPWpGaD
Crizotinib—YES1—Innate Immune System—EP300—attention deficit hyperactivity disorder	5.73e-05	0.000137	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	5.7e-05	0.000136	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	5.51e-05	0.000132	CbGpPWpGaD
Crizotinib—BMPR1B—Signaling Pathways—EP300—attention deficit hyperactivity disorder	5.47e-05	0.000131	CbGpPWpGaD
Crizotinib—IRAK1—Innate Immune System—EP300—attention deficit hyperactivity disorder	5.43e-05	0.00013	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	5.35e-05	0.000128	CbGpPWpGaD
Crizotinib—TBK1—Immune System—EP300—attention deficit hyperactivity disorder	5.35e-05	0.000128	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	5.32e-05	0.000127	CbGpPWpGaD
Crizotinib—JAK2—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	5.29e-05	0.000127	CbGpPWpGaD
Crizotinib—TYK2—Innate Immune System—EP300—attention deficit hyperactivity disorder	5.27e-05	0.000126	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	5.26e-05	0.000126	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	5.18e-05	0.000124	CbGpPWpGaD
Crizotinib—SRC—Disease—SNAP25—attention deficit hyperactivity disorder	5.13e-05	0.000123	CbGpPWpGaD
Crizotinib—MAP3K3—Immune System—EP300—attention deficit hyperactivity disorder	5.13e-05	0.000123	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	4.99e-05	0.000119	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	4.98e-05	0.000119	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	4.96e-05	0.000119	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	4.95e-05	0.000118	CbGpPWpGaD
Crizotinib—JAK3—Immune System—EP300—attention deficit hyperactivity disorder	4.84e-05	0.000116	CbGpPWpGaD
Crizotinib—LYN—Developmental Biology—EP300—attention deficit hyperactivity disorder	4.84e-05	0.000116	CbGpPWpGaD
Crizotinib—ABCB1—Transmembrane transport of small molecules—SLC6A3—attention deficit hyperactivity disorder	4.83e-05	0.000116	CbGpPWpGaD
Crizotinib—ABL1—Developmental Biology—EP300—attention deficit hyperactivity disorder	4.81e-05	0.000115	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	4.81e-05	0.000115	CbGpPWpGaD
Crizotinib—JAK2—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	4.81e-05	0.000115	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	4.79e-05	0.000115	CbGpPWpGaD
Crizotinib—FES—Signaling Pathways—EP300—attention deficit hyperactivity disorder	4.78e-05	0.000114	CbGpPWpGaD
Crizotinib—LYN—Hemostasis—EP300—attention deficit hyperactivity disorder	4.74e-05	0.000114	CbGpPWpGaD
Crizotinib—ABL1—Hemostasis—EP300—attention deficit hyperactivity disorder	4.72e-05	0.000113	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	4.71e-05	0.000113	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	4.65e-05	0.000111	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	4.63e-05	0.000111	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—ADRA2C—attention deficit hyperactivity disorder	4.6e-05	0.00011	CbGpPWpGaD
Crizotinib—JAK2—Developmental Biology—EP300—attention deficit hyperactivity disorder	4.52e-05	0.000108	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	4.48e-05	0.000107	CbGpPWpGaD
Crizotinib—ABCB1—Integrated Pancreatic Cancer Pathway—EP300—attention deficit hyperactivity disorder	4.44e-05	0.000106	CbGpPWpGaD
Crizotinib—JAK2—Hemostasis—EP300—attention deficit hyperactivity disorder	4.44e-05	0.000106	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	4.42e-05	0.000106	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	4.41e-05	0.000106	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	4.36e-05	0.000104	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	4.35e-05	0.000104	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	4.33e-05	0.000104	CbGpPWpGaD
Crizotinib—IGF1R—Signaling Pathways—EP300—attention deficit hyperactivity disorder	4.32e-05	0.000104	CbGpPWpGaD
Crizotinib—RIPK2—Immune System—EP300—attention deficit hyperactivity disorder	4.31e-05	0.000103	CbGpPWpGaD
Crizotinib—LYN—Innate Immune System—EP300—attention deficit hyperactivity disorder	4.27e-05	0.000102	CbGpPWpGaD
Crizotinib—ABL1—Innate Immune System—EP300—attention deficit hyperactivity disorder	4.25e-05	0.000102	CbGpPWpGaD
Crizotinib—PTK2B—Immune System—EP300—attention deficit hyperactivity disorder	4.25e-05	0.000102	CbGpPWpGaD
Crizotinib—MAPK7—Signaling Pathways—EP300—attention deficit hyperactivity disorder	4.23e-05	0.000101	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—TPH2—attention deficit hyperactivity disorder	4.21e-05	0.000101	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—CACNB2—attention deficit hyperactivity disorder	4.21e-05	0.000101	CbGpPWpGaD
Crizotinib—CDK7—Disease—EP300—attention deficit hyperactivity disorder	4.17e-05	9.99e-05	CbGpPWpGaD
Crizotinib—BLK—Immune System—EP300—attention deficit hyperactivity disorder	4.15e-05	9.93e-05	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—DPYD—attention deficit hyperactivity disorder	4.14e-05	9.92e-05	CbGpPWpGaD
Crizotinib—FGR—Immune System—EP300—attention deficit hyperactivity disorder	4.13e-05	9.89e-05	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	4.13e-05	9.88e-05	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	4.07e-05	9.74e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	4.06e-05	9.71e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	4.06e-05	9.71e-05	CbGpPWpGaD
Crizotinib—JAK2—Innate Immune System—EP300—attention deficit hyperactivity disorder	4e-05	9.57e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	3.93e-05	9.4e-05	CbGpPWpGaD
Crizotinib—LCK—Hemostasis—EP300—attention deficit hyperactivity disorder	3.89e-05	9.31e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	3.86e-05	9.25e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	3.86e-05	9.24e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	3.86e-05	9.24e-05	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—CACNA1C—attention deficit hyperactivity disorder	3.85e-05	9.22e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	3.81e-05	9.13e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	3.75e-05	8.97e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	3.59e-05	8.59e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	3.55e-05	8.5e-05	CbGpPWpGaD
Crizotinib—SRC—Developmental Biology—EP300—attention deficit hyperactivity disorder	3.51e-05	8.4e-05	CbGpPWpGaD
Crizotinib—LCK—Innate Immune System—EP300—attention deficit hyperactivity disorder	3.5e-05	8.38e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	3.48e-05	8.32e-05	CbGpPWpGaD
Crizotinib—SRC—Hemostasis—EP300—attention deficit hyperactivity disorder	3.44e-05	8.24e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	3.42e-05	8.18e-05	CbGpPWpGaD
Crizotinib—PTK2—Immune System—EP300—attention deficit hyperactivity disorder	3.38e-05	8.1e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	3.38e-05	8.08e-05	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—SNAP25—attention deficit hyperactivity disorder	3.37e-05	8.06e-05	CbGpPWpGaD
Crizotinib—YES1—Immune System—EP300—attention deficit hyperactivity disorder	3.34e-05	7.99e-05	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—ADRA2A—attention deficit hyperactivity disorder	3.2e-05	7.67e-05	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—TPH2—attention deficit hyperactivity disorder	3.18e-05	7.61e-05	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—CACNB2—attention deficit hyperactivity disorder	3.18e-05	7.61e-05	CbGpPWpGaD
Crizotinib—IRAK1—Immune System—EP300—attention deficit hyperactivity disorder	3.16e-05	7.57e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	3.14e-05	7.53e-05	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—EP300—attention deficit hyperactivity disorder	3.13e-05	7.48e-05	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—DPYD—attention deficit hyperactivity disorder	3.13e-05	7.48e-05	CbGpPWpGaD
Crizotinib—SRC—Innate Immune System—EP300—attention deficit hyperactivity disorder	3.1e-05	7.42e-05	CbGpPWpGaD
Crizotinib—TYK2—Immune System—EP300—attention deficit hyperactivity disorder	3.07e-05	7.35e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	3.04e-05	7.27e-05	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—CACNA1C—attention deficit hyperactivity disorder	2.91e-05	6.96e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	2.84e-05	6.8e-05	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—ADRA2C—attention deficit hyperactivity disorder	2.84e-05	6.79e-05	CbGpPWpGaD
Crizotinib—TYK2—Disease—EP300—attention deficit hyperactivity disorder	2.84e-05	6.79e-05	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—EP300—attention deficit hyperactivity disorder	2.79e-05	6.67e-05	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—EP300—attention deficit hyperactivity disorder	2.75e-05	6.57e-05	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—EP300—attention deficit hyperactivity disorder	2.63e-05	6.29e-05	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—COMT—attention deficit hyperactivity disorder	2.55e-05	6.11e-05	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—EP300—attention deficit hyperactivity disorder	2.55e-05	6.1e-05	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—SNAP25—attention deficit hyperactivity disorder	2.54e-05	6.08e-05	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—MAOA—attention deficit hyperactivity disorder	2.53e-05	6.06e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	2.49e-05	5.96e-05	CbGpPWpGaD
Crizotinib—LYN—Immune System—EP300—attention deficit hyperactivity disorder	2.49e-05	5.95e-05	CbGpPWpGaD
Crizotinib—ABL1—Immune System—EP300—attention deficit hyperactivity disorder	2.48e-05	5.93e-05	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—ADRA2A—attention deficit hyperactivity disorder	2.42e-05	5.79e-05	CbGpPWpGaD
Crizotinib—JAK2—Immune System—EP300—attention deficit hyperactivity disorder	2.33e-05	5.57e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	2.2e-05	5.27e-05	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—EP300—attention deficit hyperactivity disorder	2.19e-05	5.23e-05	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—EP300—attention deficit hyperactivity disorder	2.16e-05	5.16e-05	CbGpPWpGaD
Crizotinib—JAK2—Disease—EP300—attention deficit hyperactivity disorder	2.15e-05	5.14e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—EP300—attention deficit hyperactivity disorder	2.05e-05	4.9e-05	CbGpPWpGaD
Crizotinib—LCK—Immune System—EP300—attention deficit hyperactivity disorder	2.04e-05	4.88e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—EP300—attention deficit hyperactivity disorder	1.99e-05	4.75e-05	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—TPH2—attention deficit hyperactivity disorder	1.96e-05	4.69e-05	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—CACNB2—attention deficit hyperactivity disorder	1.96e-05	4.69e-05	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—DPYD—attention deficit hyperactivity disorder	1.93e-05	4.61e-05	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—COMT—attention deficit hyperactivity disorder	1.93e-05	4.61e-05	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—MAOA—attention deficit hyperactivity disorder	1.91e-05	4.58e-05	CbGpPWpGaD
Crizotinib—LCK—Disease—EP300—attention deficit hyperactivity disorder	1.88e-05	4.51e-05	CbGpPWpGaD
Crizotinib—SRC—Immune System—EP300—attention deficit hyperactivity disorder	1.8e-05	4.32e-05	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—CACNA1C—attention deficit hyperactivity disorder	1.79e-05	4.29e-05	CbGpPWpGaD
Crizotinib—SRC—Disease—EP300—attention deficit hyperactivity disorder	1.67e-05	3.99e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—EP300—attention deficit hyperactivity disorder	1.61e-05	3.85e-05	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—SNAP25—attention deficit hyperactivity disorder	1.57e-05	3.75e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—EP300—attention deficit hyperactivity disorder	1.5e-05	3.6e-05	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—ADRA2A—attention deficit hyperactivity disorder	1.49e-05	3.57e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—EP300—attention deficit hyperactivity disorder	1.32e-05	3.16e-05	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—COMT—attention deficit hyperactivity disorder	1.19e-05	2.84e-05	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—MAOA—attention deficit hyperactivity disorder	1.18e-05	2.82e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—EP300—attention deficit hyperactivity disorder	1.17e-05	2.79e-05	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—EP300—attention deficit hyperactivity disorder	1.09e-05	2.62e-05	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—EP300—attention deficit hyperactivity disorder	8.26e-06	1.98e-05	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—EP300—attention deficit hyperactivity disorder	5.09e-06	1.22e-05	CbGpPWpGaD
